Camgenium specialises in rapid development and deployment of regulatory compliant medical AI models, software and connected hardware medical devices. Established in 2007, Camgenium has a reputation for regulatory excellence, working to standards including ISO 13485, ISO 27001 and GxP.
Camgenium has developed market-leading AI solutions derived from >100m global healthcare records as well as software products that have been deployed worldwide to tens of thousands of patients. Camgenium is certified by the NHS to access national data sets for development of AI and ML algorithms.
Cambridge based Camgenium has a client-centric approach, offering a complete service model from initial product concept through development, production, and deployment to decommissioning. The company is able to take regulatory responsibility for the whole product lifecycle and can deploy globally. Camgenium has assembled a best-in-class expert team of engineers, scientists and mathematicians. The team’s commitment to excellence is demonstrated by its pro bono work teaching medical device design to students at Cambridge University Engineering Department.
Camgenium is the trading name of L2S2 Ltd.
Camgenium has developed market-leading AI solutions derived from >100m global healthcare records as well as software products that have been deployed worldwide to tens of thousands of patients. Camgenium is certified by the NHS to access national data sets for development of AI and ML algorithms.
Cambridge based Camgenium has a client-centric approach, offering a complete service model from initial product concept through development, production, and deployment to decommissioning. The company is able to take regulatory responsibility for the whole product lifecycle and can deploy globally. Camgenium has assembled a best-in-class expert team of engineers, scientists and mathematicians. The team’s commitment to excellence is demonstrated by its pro bono work teaching medical device design to students at Cambridge University Engineering Department.
Camgenium is the trading name of L2S2 Ltd.
The United Kingdom is by far Canada’s most important commercial partner in Europe and, from a global perspective, ranks second only to the United States. Two-way trade between Canada and UK was valued at more than £12 billion in 2008. The UK ranks second in Foreign Direct Investment (FDI), with UK FDI stock in Canada valued at an all time high of £22 billion in 2008. The UK is also Canada’s second largest science & technology partner worldwide, with over 40% of S&T collaborations being in the field of biomedical and clinical research. . . The Commercial and Economic Division of the Canadian High Commission in London works with Canadian companies, universities and research institutes that are seeking market opportunities, collaborative R&D partnerships or technology transfer deals in the UK. We also offer confidential advice and service to UK companies interested in investing in Canada or in finding collaborative opportunities with Canadian partners.
Cancer Research Horizons is the innovation engine of Cancer Research UK – the world’s largest charitable funder of cancer research. We bring together the best minds, bold ideas, and the right partners to bridge the gap between academic research and taking drugs to market. We focus on the tougher, more profound ideas that can lead to true innovation, translating them into effective treatments and diagnostics for cancer patients.
To date we’ve played an instrumental role in forming over 70 startup companies. We’ve helped bring 11 cancer drugs to market, borne out of Cancer Research UK’s pioneering research. Through these drugs, we have enabled in excess of 6 million courses of treatment for cancer patients worldwide.
With access to Cancer Research UK’s network of 4,000 exceptional researchers, and over £400m of annual research spend, we’re a powerful partner in the fight to conquer cancer. By uniting our commercial partnerships and therapeutic innovation capabilities, Cancer Research Horizons is uniquely placed to support translational funding, entrepreneurial development, licensing and collaboration, start-up creation, and offer a full spectrum of drug discovery and clinical capabilities.
Every penny we make goes back into funding the next bold steps, to help bring forward the day when all cancers and conquered.
To date we’ve played an instrumental role in forming over 70 startup companies. We’ve helped bring 11 cancer drugs to market, borne out of Cancer Research UK’s pioneering research. Through these drugs, we have enabled in excess of 6 million courses of treatment for cancer patients worldwide.
With access to Cancer Research UK’s network of 4,000 exceptional researchers, and over £400m of annual research spend, we’re a powerful partner in the fight to conquer cancer. By uniting our commercial partnerships and therapeutic innovation capabilities, Cancer Research Horizons is uniquely placed to support translational funding, entrepreneurial development, licensing and collaboration, start-up creation, and offer a full spectrum of drug discovery and clinical capabilities.
Every penny we make goes back into funding the next bold steps, to help bring forward the day when all cancers and conquered.
Cancer Research Technology (CRT) is dedicated to advancing discoveries to beat cancer. We develop and commercialise exciting new discoveries in cancer research, working closely with leading clinical and academic institutions, pharmaceutical companies and biotechs worldwide. CRT facilitates the discovery, development and marketing of new cancer therapeutics, vaccines, diagnostics and enabling technologies. . . CRT is owned by Cancer Research UK, the world’s largest charitable funder of cancer research and we’re uniquely placed to capitalise on the research and connections of our parent organisation.
Carocell Bio are developing novel peptides to more safely and effectively treat inflammatory diseases.
Catalent, Inc. is a global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs. Catalent helps accelerate over 1,500 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply approximately 70 billion doses of nearly 8,000 products annually. Catalent’s expert workforce of nearly 18,000 includes more than 3,000 scientists and technicians.
Point of contact:
Peter F. Farmer, Senior Account Director
Peter.Farmer@catalent.com
Linkedin: https://www.linkedin.com/in/peter-farmer-62843513/
Point of contact:
Peter F. Farmer, Senior Account Director
Peter.Farmer@catalent.com
Linkedin: https://www.linkedin.com/in/peter-farmer-62843513/
No data available
Discovery services in oncology, immunology and respiratory
No data available
CPI provides assets and resources to support innovations in the manufacture of biologics. Utilising our state of the art facilities and technical expertise, we help our clients to de-risk process development through proof of concept testing to accelerate the commercialisation of new processes and technologies. . . Our skilled team of scientists, engineers and sector specialists can help companies of all sizes to develop, demonstrate, prototype and scale-up innovations that could be beneficial to biologics manufacture and provision. From initial programme scoping and planning through to process demonstration and scale-up we have a range of services which can be tailored to meet your needs. . . Collaboration with CPI will enable the biologics industry to capitalise on its strong research and development pipeline and make more therapies available for unmet clinical needs. We support the commercialisation of research by promoting collaboration with industry across the supply chain from research through to manufacture and clinic.